Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 11.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,405 shares of the biopharmaceutical company’s stock after buying an additional 1,592 shares during the quarter. Teacher Retirement System of Texas’ holdings in Agios Pharmaceuticals were worth $512,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. CWM LLC lifted its position in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 996 shares during the period. Victory Capital Management Inc. increased its position in shares of Agios Pharmaceuticals by 28.8% during the 1st quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 1,964 shares during the period. GW&K Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 19.6% in the 1st quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock worth $23,954,000 after buying an additional 134,063 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at $1,601,000. Finally, TD Asset Management Inc boosted its stake in Agios Pharmaceuticals by 7.5% during the first quarter. TD Asset Management Inc now owns 178,072 shares of the biopharmaceutical company’s stock valued at $5,218,000 after buying an additional 12,400 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the sale, the insider directly owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. The trade was a 5.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,899 shares of company stock worth $611,324 in the last quarter. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ AGIO opened at $40.67 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The business has a 50-day moving average price of $39.77 and a two-hundred day moving average price of $36.32. The firm has a market capitalization of $2.37 billion, a PE ratio of -5.81 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm’s quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $16.22 EPS. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings lowered Agios Pharmaceuticals from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday. Scotiabank cut their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a report on Monday, July 28th. Bank of America reduced their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research upgraded shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $57.25.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.